Resistance of Hepatitis B Virus to Antiviral Drugs: Current Aspects and Directions for Future Investigation
Open Access
- 1 February 2001
- journal article
- research article
- Published by SAGE Publications in Antiviral Chemistry and Chemotherapy
- Vol. 12 (1), 1-35
- https://doi.org/10.1177/095632020101200101
Abstract
Despite the existence of vaccines, chronic hepatitis B virus (HBV) infection remains a major health problem worldwide. Interferon therapy successfully controls infection in only a small percentage of chronically infected individuals. The recent approval of the nucleoside analogue lamivudine for the treatment of chronic HBV infection has ushered in a new era of antiviral therapy. While lamivudine is highly effective at controlling viral infection short-term, prolonged therapy has been associated with an increasing incidence of viral resistance. Thus, it appears that lamivudine alone will not be sufficient to control chronic viral infection in the majority of individuals. In addition to lamivudine, several new nucleoside and nucleotide analogues that show promising antihepadnaviral activity are in various stages of development. Lamivudine resistance has been found to confer cross-resistance to some of these compounds and it is likely that resistance to newer antivirals may also develop during prolonged use. Drug resistance therefore poses a major threat to nucleoside analogue-based therapies for chronic HBV infection. Fortunately, combination chemotherapy (antiviral therapy with two or more agents) can minimize the chance that resistance will develop and can be expected to achieve sustained reductions in viral load, provided that suitable combinations of agents are chosen. Here we review the basis of drug resistance in HBV, with emphasis on aspects that are likely to affect drug choice in future.Keywords
This publication has 97 references indexed in Scilit:
- Melatonin Prevents Pigment Gallstone Formation Induced by Bile Duct Ligation in Guinea PigsHepatology, 2000
- Lamivudine as Initial Treatment for Chronic Hepatitis B in the United StatesNew England Journal of Medicine, 1999
- Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapyHepatology, 1999
- Identification and characterization of mutations in hepatitis B virus resistant to lamivudineHepatology, 1998
- Lamivudine resistance inimmunocompetent chronic hepatitis BJournal of Hepatology, 1997
- Novel molecular approaches toward therapy of chronic hepatitis BArchiv für die gesamte Virusforschung, 1997
- Mutational studies of human immunodeficiency virus type 1 reverse transcriptase : the involvement of residues 183 and 184 in the fidelity of DNA synthesisFEBS Letters, 1996
- A Preliminary Trial of Lamivudine for Chronic Hepatitis B InfectionNew England Journal of Medicine, 1995
- In vivo study of the mechanism of action of antiviral agents against hepadna virus replication in the liver: Resistance of supercoiled viral DNAJournal of Hepatology, 1986
- Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cellsCell, 1986